2. Academic Validation
  3. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases

  • Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6. doi: 10.1016/j.bmcl.2011.11.019.
Patrick A Plé 1,  Frédéric Jung,  Sue Ashton,  Laurent Hennequin,  Romuald Laine,  Rémy Morgentin,  Georges Pasquet,  Sian Taylor
Affiliations

Affiliation

  • 1 AstraZeneca, Centre de Recherches, B.P. 1050, 51689 Reims Cedex 2, France. patrick.ple@astrazeneca.com
PMID: 22153662 DOI: 10.1016/j.bmcl.2011.11.019
Abstract

A new series of Quinazoline Ether Inhibitor which potently inhibits VEGFR-2 and PDGFR tyrosine kinases is described here. In vitro, pharmacokinetics and in vivo evaluations led to the selection of AZD2932.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z